TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Billy Joel announced his first official show since being diagnosed with normal pressure hydrocephalus, according to People, as reported by MedPage Today on Nov. 10, 2026. The same neurology roundup highlighted studies linking slow-wave sleep with cognitive trajectories in preclinical Alzheimer’s and identifying factors associated with faster Parkinson’s progression.
Billy Joel announced his first official show since his diagnosis of normal pressure hydrocephalus, according to People, in a development reported Nov. 10 by MedPage Today. The same neurology roundup covered research associating slow-wave sleep with cognitive trajectories in preclinical Alzheimer’s disease and identifying clinical features linked with faster Parkinson’s disease progression.
The report said Joel had announced a return to performing, but did not provide the show date, venue or other details. It also did not describe his current health or explain what the performance would involve. The announcement marks a planned stage appearance following his diagnosis, but the report does not establish a broader return schedule.
Two research findings were among the roundup’s other developments. A study in Alzheimer’s Research & Therapy linked slow-wave sleep with cognitive trajectories among people with preclinical Alzheimer’s disease; the association may have been stronger in men, the report said. An Italian cohort study published in the Journal of Neurology, Neurosurgery & Psychiatry associated older age, bilateral symmetric parkinsonism and rapid eye movement sleep behavior disorder at diagnosis with faster Parkinson’s progression.
The roundup also summarized findings across other areas of neurology. PepGen reported positive topline results from a phase II study of investigational PGN-EDODM1 in myotonic dystrophy type 1, while case-series data indicated a high rate of later symptomatic brain hemorrhage among patients with iatrogenic cerebral amyloid angiopathy. These are separate developments, and the brief report does not provide detailed results or establish how they may affect clinical practice.
Joel’s Return and Neurology Research
Joel’s announcement is of interest to fans because it signals a planned public performance after his normal pressure hydrocephalus diagnosis. The available report, however, confirms an announced show rather than a completed performance or a sustained return to touring. Without a date or further details, readers cannot tell how the appearance fits into his plans.
The research findings matter for a different reason: they point to factors scientists are studying in neurodegenerative disease. Sleep patterns and features observed at Parkinson’s diagnosis may help researchers understand differences in cognitive change or disease progression. The reported associations do not show that sleep causes a particular cognitive outcome or that the listed Parkinson’s features determine an individual’s course. They are findings from studies, not individualized predictions.
Popular right now
Dyson Airsmooth Styling Brush
Dyson V15 Detect Cordless Vacuum
Vitamix Touch & Go Advance 32-Ounce Bar Blender, White
As an affiliate, we earn on qualifying purchases.
The Studies Behind the Roundup
MedPage Today’s Nov. 10 item was a short neurology and neuroscience roundup by Judy George, the outlet’s deputy managing editor. It assembled developments reported elsewhere, including Joel’s announcement as covered by People and research published in specialist journals. It was not a single study or a detailed account of every finding.
The roundup noted that some results had been presented earlier at the American Academy of Neurology’s annual meeting before later publication. These included final open-label trial data on the CD19-directed CAR T-cell therapy mivocabtagene autoleucel for stiff person syndrome and phase III data on azetukalner for focal seizures. It also cited a New England Journal of Medicine correspondence describing an initial proof of concept for chemogenetic neuromodulation in drug-resistant epilepsy.
Other items included a Swedish case-control study linking workplace exposure to petroleum-derived lubricants with higher multiple sclerosis risk, and a study of people treated for overactive bladder that found beta-3 agonists were not associated with lower dementia incidence than anticholinergics. These reports address distinct populations and questions; the roundup did not supply enough detail to compare their methods or quantify the findings.
“Billy Joel announced his first official show since his normal pressure hydrocephalus diagnosis.”
— MedPage Today, reporting on People
Show Details and Study Limits
The roundup did not state when or where Joel will perform, whether the show has since taken place, or whether he plans additional appearances. It also provided no further information about his health or the implications of his diagnosis for performing.
For the Alzheimer’s and Parkinson’s findings, the brief summaries leave key details unspecified, including study size, follow-up periods and the measures used to assess cognition or progression. The Parkinson’s factors were reported as associations in an Italian cohort; the summary does not say how strongly each factor predicted outcomes or whether the results apply to other populations. The slow-wave sleep finding likewise does not establish cause and effect.
Awaiting Performance and Research Details
The immediate next detail to watch for is the date and location of Joel’s announced show, along with any information from his representatives about additional performances. The source material does not give a timetable for those details.
For the research, fuller interpretation depends on the underlying journal papers and subsequent studies. The roundup does not report changes to clinical guidance or confirm that any of the findings have altered patient care. Readers should treat the reported links as research observations, not as diagnoses or predictions about a particular person’s health.
Key Questions
What did Billy Joel announce?
According to People, as cited by MedPage Today, Joel announced his first official show since his normal pressure hydrocephalus diagnosis.
When and where is the show?
The Nov. 10 roundup did not provide a date or venue. It also did not say whether the performance had already happened.
What did the Alzheimer’s sleep study report?
It linked slow-wave sleep with cognitive trajectories in people with preclinical Alzheimer’s disease. The report said the association may have been stronger in men; it did not establish that sleep caused a particular outcome.
Which factors were associated with faster Parkinson’s progression?
The Italian cohort study associated older age, bilateral symmetric parkinsonism and REM sleep behavior disorder at diagnosis with faster progression. These are reported group-level associations, not a certain prediction for an individual.
Source: medpagetoday.com
